Study of extra treatment for stage III papillary kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether extra treatment after surgery can help people with a certain type of kidney cancer (stage III papillary kidney cancer) that is at high risk of coming back. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have papillary kidney cancer confirmed by a biopsy.
- Your cancer must be stage III and been removed completely with surgery.
- A special test must show you are at high risk for the cancer returning.
- You must be in good health (able to do daily activities with little or no trouble).
- You must not have had any cancer treatment before your surgery.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests whether the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. It is for people with a less common type of kidney cancer called non-clear cell renal cell carcinoma that was at a higher stage or had spread but was fully removed.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests combining the immunotherapy drug pembrolizumab with the targeted therapy lenvatinib for people with advanced clear cell kidney cancer that returned after completing pembrolizumab as an early treatment after surgery. It aims to see if this combination can shrink or control the cancer.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Hear when a new Papillary Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.